Nicholas Fischer | 20-ERD-004
We aim to design a versatile nanoplatform for the development and delivery (into the bodies of patients) of nucleic acid-based therapeutics with specially encoded proteins that promote the production of vaccine antigens. If successful, this platform would reduce the time from concept to administration of the therapeutic from months to days, providing a powerful defense against biological threats and disease.
Publications, Presentations, and Patents
Fischer, N. 2020. "Cationic HDL mimetics enhance in vivo delivery of self-replicating mRNA." Nanomed-Nanotechnol 24. doi:10.1016/j.nano.2020.102154. LLNL-JRNL-747570